CLARINEX Drug Patent Profile

When do Clarinex patents expire, and when can generic versions of Clarinex launch?

Clarinex is a drug marketed by Organon Llc and Organon and is included in five NDAs.

The generic ingredient in CLARINEX is desloratadine; pseudoephedrine sulfate. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the desloratadine; pseudoephedrine sulfate profile page.

Summary for CLARINEX

US Patents:	0
Applicants:	2
NDAs:	5
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	19
Patent Applications:	5,731
Drug Prices:	Drug price information for CLARINEX
What excipients (inactive ingredients) are in CLARINEX?	CLARINEX excipients list
DailyMed Link:	CLARINEX at DailyMed

See drug prices for CLARINEX

See drug sales revenues for CLARINEX

Recent Clinical Trials for CLARINEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
J. Uriach and Company	Phase 1
Derm Research, PLLC	Phase 4
UCB Pharma	Phase 4

See all CLARINEX clinical trials

Pharmacology for CLARINEX

Drug Class	Histamine-1 Receptor Antagonist
Mechanism of Action	Histamine H1 Receptor Antagonists

Paragraph IV (Patent) Challenges for CLARINEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CLARINEX	Oral Solution	desloratadine	0.5 mg/mL	021300	1	2008-05-08
CLARINEX	Orally Disintegrating Tablets	desloratadine	2.5 mg and 5 mg	021165	3	2006-06-21

US Patents and Regulatory Information for CLARINEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Llc	CLARINEX	desloratadine	SOLUTION;ORAL	021300-001	Sep 1, 2004		DISCN	Yes	No
Organon	CLARINEX	desloratadine	TABLET;ORAL	021165-001	Dec 21, 2001	AB	RX	Yes	Yes
Organon	CLARINEX	desloratadine	TABLET, ORALLY DISINTEGRATING;ORAL	021312-002	Jul 14, 2005		DISCN	Yes	No

Expired US Patents for CLARINEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	CLARINEX	desloratadine	TABLET, ORALLY DISINTEGRATING;ORAL	021312-001	Jun 26, 2002	4,863,931*PED
Organon	CLARINEX	desloratadine	TABLET, ORALLY DISINTEGRATING;ORAL	021312-001	Jun 26, 2002	7,214,684*PED
Organon	CLARINEX	desloratadine	TABLET, ORALLY DISINTEGRATING;ORAL	021312-002	Jul 14, 2005	7,214,684*PED

EU/EMA Drug Approvals for CLARINEX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Actavis Group PTC ehf	Desloratadine Actavis	desloratadine	EMEA/H/C/002435Treatment of allergic rhinitis and urticaria.	Authorised	yes	no	no	2012-01-13
N.V. Organon	Azomyr	desloratadine	EMEA/H/C/000310Azomyr is indicated for the relief of symptoms associated with:allergic rhinitis (see section 5.1)urticaria (see section 5.1)	Authorised	no	no	no	2001-01-15
Ratiopharm GmbH	Desloratadine ratiopharm	desloratadine	EMEA/H/C/002404Desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician	Authorised	yes	no	no	2012-01-13

International Patents for CLARINEX

See the table below for patents covering CLARINEX around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	H05500956
Germany	60028710
European Patent Office	0494972	PRESENTATION SOUS FORME EFFERVESCENTE D'UN MEDICAMENT A USAGE PEDIATRIQUE (EFFERVESCENT DOSAGE FORM AND METHOD OF ADMINISTERING SAME)

Supplementary Protection Certificates for CLARINEX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1110543	1/2008	Austria		PRODUCT NAME: DESLORATADIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, KOMBINIERT MIT PSEUDOEPHEDRIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER ESTERS; REGISTRATION NO/DATE: EU/1/07/399/001-006 20070730
1110543	91403	Luxembourg		91403, EXPIRES: 20220730
1110543	SZ 1/2008	Austria		PRODUCT NAME: DESLORATADIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, KOMBINIERT MIT PSEUDOEPHEDRIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER ESTERS

Market Dynamics and Financial Trajectory for CLARINEX

Last updated: February 19, 2026

What Is CLARINEX and Its Current Market Position?

CLARINEX (containing the active ingredient desloratadine) targets allergic rhinitis and chronic urticaria. Approved by the FDA in 2003, it is marketed by Bayer and Allergan (now part of AbbVie). It competes primarily with loratadine, cetirizine, and fexofenadine. Its patent expired in the U.S. in 2018, leading to increased generic competition.

Market Size and Growth Trends

The global antihistamine market, valued at approximately $4.2 billion in 2022, is projected to reach $6.2 billion by 2030 at a compound annual growth rate (CAGR) of 5.2% (Research, 2022). Desloratadine accounts for roughly 40% of this market segment, driven by its favorable efficacy and safety profile.

Key Market Drivers

• Increasing prevalence of allergic rhinitis and urticaria
• Growing awareness and diagnosis rates
• Expanding pharmaceutical distribution channels in emerging markets
• Introduction of over-the-counter (OTC) formulations in select regions

Market Challenges

• Patent expirations causing price erosion
• Surge in generic drug availability
• Competition from other second-generation antihistamines
• Regulatory pressures on pricing and marketing in some regions

Financial Performance and Trends

Revenue and Sales Data

Before patent expiry, CLARINEX generated annual revenues exceeding $1.2 billion globally (2017). Post-patent, sales declined due to generics entering the market, with current estimates suggesting global revenues at around $500 million in 2022.

R&D and Investment Trends

• Bayer and associated companies have shifted focus towards biosimilars and biologics, reducing investment in new small-molecule antihistamines.
• No recent major investments or pipeline developments directly targeting desloratadine or CLARINEX branding are reported.

Pricing Dynamics

• Patent expiry led to generic versions priced at 30–50% lower than branded CLARINEX.
• OTC formulations are priced even lower, expanding accessibility but squeezing branded sales.

Competitive Landscape

Player	Product	Market Share (Approximate)	Key Attributes
Bayer	CLARINEX	40%	Efficacy, safety profile
Sandoz	Desloratadine generics	25%	Cost competitiveness
Johnson & Johnson	Zyrtec (cetirizine)	20%	Broad acceptance
Others	Various	15%	Regional players, OTC products

Generic manufacturers have captured a significant share since patent loss. Brand dominance persists mainly in emerging markets and for prescriptions in developed markets.

Regulatory and Policy Influence

• In some countries, regulators have approved OTC switches for desloratadine, affecting sales channels.
• Price controls in regions like Europe limit revenue growth for branded drugs.
• Patent litigations and exclusivity extensions or challenges impact product availability and market timing.

Future Outlook

The trajectory of CLARINEX and desloratadine will depend on:

• Potential reformulation or combination therapy developments
• Generic pricing strategies and market penetration
• Shift toward OTC availability reducing prescription-based revenues
• Regulatory changes influencing access and reimbursement policies

The antihistamine market is mature. Growth relies on expanding into new geographical regions and integrating digital health tools for patient management.

---

Key Takeaways

• CLARINEX's market share diminished post-patent expiration, with generic versions dominating sales.
• The global antihistamine market is growing at a moderate rate, driven by allergy prevalence.
• Pricing pressures and OTC switches significantly impact branded drug revenues.
• No recent pipeline developments suggest limited future innovation or repositioning for CLARINEX.
• Future growth depends on geographic expansion, regulatory shifts, and potential combination therapies.

FAQs

1. What caused the decline in CLARINEX's sales post-2018?
   Patent expiration led to the entrance of generics, causing price erosion and market share loss.

2. Are there any new formulations or indications for CLARINEX?
   No recent approved new formulations or indications are publicly reported.

3. What regions are still lucrative for branded CLARINEX sales?
   Emerging markets and prescription channels in developed countries maintain some branded sales due to brand loyalty and regulatory differences.

4. How is the competition impacting pricing strategies?
   The proliferation of generics has driven prices down significantly, pressuring branded manufacturers to adopt aggressive pricing.

5. What are the prospects for CLARINEX in the OTC market?
   OTC availability broadens access but reduces prescribed sales, shifting revenue streams toward volume rather than premium pricing.

---

References

[1] Market Research Future. (2022). Antihistamines Market Size, Share and Trends Analysis.
[2] Bayer AG. (2017). Annual Report.
[3] U.S. Food and Drug Administration. (2003). Approval of Desloratadine.
[4] IMS Health (2022). Pharmaceutical Market Analysis.